POST Online Media Lite Edition


Teva announces changes to executive leadership team

Staff writer |
Jerusalem, Israel - November 6, 2012, Jerusalem, Israel - Teva Pharmaceutical Industries Ltd. announces that Allan Oberman, SVP of North America Generic Pharmaceuticals of Teva, has been appointed president and CEO of Teva Americas Generics.

Mr. Oberman has served as Senior Vice President of North America Generic Pharmaceuticals since earlier this year. Mr. Oberman first joined Teva in 2000 and has served as President of Teva EMIA (Eastern Europe, Middle East, Israel and Africa). He also served as the Chief Operating Officer of the Teva International Group and prior to that, as President and CEO of Teva Canada.

Previously, Mr. Oberman was the President of Best Foods Canada Inc. He also served as Chairman of the Canadian Generic Pharmaceutical Association (CGPA) in 2007 – 2008. Mr. Oberman holds an MBA from the Schulich School of Business – York University and a BA from the University of Western Ontario.

The Company also announced the appointment of Jill DeSimone to the newly created position of Senior Vice President and General Manager of Teva Global Women’s Health, overseeing all aspects of Teva's Women's Health franchise.

Ms. DeSimone has many years of experience, joining Teva from Bristol-Myers Squibb (BMS), where she has held various global leadership positions, most as Senior Vice President, U.S. Commercialization Excellence. Ms. DeSimone also held previous roles in BMS’ U.S. Oncology and Virology business units, where she was highly successful in developing important franchises.

Ms. DeSimone is a Wharton Graduate Fellow, having completed an Executive Fellowship at the Wharton School of Business. She also holds a BS in Pharmacy from Northeastern University. Ms. DeSimone serves on the Board of Directors for the Children’s Health Fund (NY) and Aids United Washington (DC).

Teva also announced that as part of the succession, William S. Marth will step down as President and CEO of Teva Americas effective immediately and retire at the end of 2013.

Mr. Marth has served as President & Chief Executive Officer Americas since June 2010, after serving as President and Chief Executive Officer of Teva North America from January 2008 to June 2010 and as President and Chief Executive Officer of Teva USA from January 2005 to January 2008. Mr. Marth was previously Executive Vice President and Vice President of Sales and Marketing for Teva USA.

Prior to joining Teva USA, Mr. Marth had held various positions with the Apothecon division of Bristol-Myers Squibb. Mr. Marth earned his B.Sc. in pharmacy from the University of Illinois in 1977 and his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University. Mr. Marth is a licensed pharmacist and serves on various boards and committees, including The University of the Sciences in Philadelphia and the Board of Ambassadors for John 'Hopkins' Project RESTORE.


Nano Dimension appoints Miri Naveh to board
Teva says CFO Michael McClellan will step down
MaxQ AI announces Tom Neufelder as chief technology officer
SodaStream appoints Bryan Welsh as general manager of SodaStream USA
Protalix BioTherapeutic appoints David Granot to board

What to read next

Enzymotec appoints Erez Israeli as CEO
MediWound appoints Aharon Yaari to board
Teva: Dipankar Bhattacharjee new CEO of Global Generic Medicines